We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Illumina Stock Surges 74.8% in a Year: What's Fueling the Drive?
Read MoreHide Full Article
Key Takeaways
Illumina shares surged 74.8% in a year, driven by sequencing growth and strategic expansion.
Illumina raised 2026 revenue guidance to $4.64-$4.66 billion and adjusted EPS to $5.40-$5.45.
Illumina's NovaSeq X adoption, clinical demand and multiomics innovations continue to support growth.
Illumina (ILMN - Free Report) shares have delivered strong returns over the past year, surging 74.8%. The stock has outpaced the industry’s 6% gain and the S&P 500 composite’s 9.8% rise.
Carrying a Zacks Rank #3 (Hold) at present, the renowned genomics company is advancing its core sequencing franchise while expanding into multiomics, data and software, supported by sustained clinical demand. Rising adoption of next-generation sequencing (NGS)-based diagnostics, clinical sequencing demand and new assay development support growth. The company also continues to drive NovaSeq X adoption, with strong placements and ongoing customer transitions.
San Diego, CA-based Illumina provides sequencing and array-based solutions for genetic and genomic analysis. The products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. The company’s sequencing technology, sequencing by synthesis (SBS), is adopted worldwide and supports both single-read and paired-end libraries. Outside the United States, Illumina has sales offices throughout Europe, the Asia-Pacific region and Brazil, as well as manufacturing and research facilities in Singapore and the United Kingdom.
Factors Supporting ILMN’s Price Rally
The rally in the company’s share price can be linked to its continued progress in the growth strategy. Following the June 2024 GRAIL spin-off, Illumina remains centered on its core sequencing franchise while extending into multiomics, data and software. In the third quarter of 2026, revenues, excluding tariff refunds, reached $1.17 billion, while Rest of World organic revenues grew 4.7%, driven by sustained clinical demand. Reflecting this momentum, management raised its full-year 2026 revenue guidance to $4.64-$4.66 billion and adjusted earnings per share (EPS) guidance to $5.40-$5.45, both excluding tariff refunds. Adjusted operating margin guidance also increased to 23.6%.
Image Source: Zacks Investment Research
Illumina continues to benefit from wider adoption of NGS-based diagnostics and sequencing-intensive clinical applications. Clinical sequencing consumables revenues increased 14% on a Rest of World basis in the third quarter of 2026, following 15% growth in the second quarter. Sequencing output on connected high- and mid-throughput instruments also remained more than 30% above the prior-year level. Management noted continued growth in on-market clinical tests and an expanding pipeline of new assays.
The company also placed more than 80 NovaSeq X systems in the third quarter of 2026, bringing placements over the preceding four quarters to approximately. Nearly 84% of high-throughput sequencing volumes and 60% of revenues had transitioned to NovaSeq X. Clinical volume conversion remained at 78%, with management expecting 80%-85% adoption in the coming quarters.
Beyond sequencing, Illumina is extending its multiomics and data capabilities through SomaScan, SomaSeq, StrataMap Spatial and BioInsight. In October 2026, Illumina launched its BioInsight platform, combining analysis applications, AI models and curated biological data. Its Billion Cell Atlas has progressed beyond the halfway point, with GSK joining the biopharma consortium. The company also introduced SpliceAI2, which identified 17% more disease-relevant splice variants than competing models in rare disease research data sets.
What Ails ILMN?
Illumina continues to operate in a higher-cost environment shaped by tariffs, freight and component inflation. The company’s research and academic demand remains tied to customer funding visibility, leaving the business exposed to grant uncertainty and restrained institutional spending.
A Glance at ILMN’s Estimates
The Zacks Consensus Estimate projects ILMN's EPS to grow 11.8% to $5.36 in 2026 and another 14.7% to $6.10 in 2027. In the past 30 days, the consensus estimate for the 2026 EPS has risen 0.9%.
Revenues are expected to increase 6.7% to $4.63 billion in 2026, followed by 6.8% growth to $4.95 billion in 2027.
Bausch + Lomb has an estimated long-term growth rate of 40.1% compared with the industry’s 15.2% growth. Shares of the company have rallied 43.3% compared with the industry’s 9.9% gain over the past year. BLCO’s earnings outpaced estimates in two of the trailing four quarters, matched once and missed on another occasion, the average surprise being 21.67%.
Insulet, sporting a Zacks Rank #1, has an estimated long-term growth rate of 19.4%, compared with the industry’s 9.3% growth. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 17.43%. PODD shares have dipped 59.6% compared with the industry’s 20.7% decline over the past year.
IDEXX Laboratories, carrying a Zacks Rank #2 (Buy), has an earnings yield of 2.2% against the industry’s negative 2.3% yield. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 5.5%. IDXX shares have risen 0.2% compared with the industry’s 2.4% growth over the past year.
Image: Bigstock
Illumina Stock Surges 74.8% in a Year: What's Fueling the Drive?
Key Takeaways
Illumina (ILMN - Free Report) shares have delivered strong returns over the past year, surging 74.8%. The stock has outpaced the industry’s 6% gain and the S&P 500 composite’s 9.8% rise.
Carrying a Zacks Rank #3 (Hold) at present, the renowned genomics company is advancing its core sequencing franchise while expanding into multiomics, data and software, supported by sustained clinical demand. Rising adoption of next-generation sequencing (NGS)-based diagnostics, clinical sequencing demand and new assay development support growth. The company also continues to drive NovaSeq X adoption, with strong placements and ongoing customer transitions.
San Diego, CA-based Illumina provides sequencing and array-based solutions for genetic and genomic analysis. The products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. The company’s sequencing technology, sequencing by synthesis (SBS), is adopted worldwide and supports both single-read and paired-end libraries. Outside the United States, Illumina has sales offices throughout Europe, the Asia-Pacific region and Brazil, as well as manufacturing and research facilities in Singapore and the United Kingdom.
Factors Supporting ILMN’s Price Rally
The rally in the company’s share price can be linked to its continued progress in the growth strategy. Following the June 2024 GRAIL spin-off, Illumina remains centered on its core sequencing franchise while extending into multiomics, data and software. In the third quarter of 2026, revenues, excluding tariff refunds, reached $1.17 billion, while Rest of World organic revenues grew 4.7%, driven by sustained clinical demand. Reflecting this momentum, management raised its full-year 2026 revenue guidance to $4.64-$4.66 billion and adjusted earnings per share (EPS) guidance to $5.40-$5.45, both excluding tariff refunds. Adjusted operating margin guidance also increased to 23.6%.
Image Source: Zacks Investment Research
Illumina continues to benefit from wider adoption of NGS-based diagnostics and sequencing-intensive clinical applications. Clinical sequencing consumables revenues increased 14% on a Rest of World basis in the third quarter of 2026, following 15% growth in the second quarter. Sequencing output on connected high- and mid-throughput instruments also remained more than 30% above the prior-year level. Management noted continued growth in on-market clinical tests and an expanding pipeline of new assays.
The company also placed more than 80 NovaSeq X systems in the third quarter of 2026, bringing placements over the preceding four quarters to approximately. Nearly 84% of high-throughput sequencing volumes and 60% of revenues had transitioned to NovaSeq X. Clinical volume conversion remained at 78%, with management expecting 80%-85% adoption in the coming quarters.
Beyond sequencing, Illumina is extending its multiomics and data capabilities through SomaScan, SomaSeq, StrataMap Spatial and BioInsight. In October 2026, Illumina launched its BioInsight platform, combining analysis applications, AI models and curated biological data. Its Billion Cell Atlas has progressed beyond the halfway point, with GSK joining the biopharma consortium. The company also introduced SpliceAI2, which identified 17% more disease-relevant splice variants than competing models in rare disease research data sets.
What Ails ILMN?
Illumina continues to operate in a higher-cost environment shaped by tariffs, freight and component inflation. The company’s research and academic demand remains tied to customer funding visibility, leaving the business exposed to grant uncertainty and restrained institutional spending.
A Glance at ILMN’s Estimates
The Zacks Consensus Estimate projects ILMN's EPS to grow 11.8% to $5.36 in 2026 and another 14.7% to $6.10 in 2027. In the past 30 days, the consensus estimate for the 2026 EPS has risen 0.9%.
Revenues are expected to increase 6.7% to $4.63 billion in 2026, followed by 6.8% growth to $4.95 billion in 2027.
Key Picks
Some better-ranked stocks in the broader medical space are Bausch + Lomb Corp. (BLCO - Free Report) , Insulet (PODD - Free Report) and IDEXX Laboratories (IDXX - Free Report) .
Bausch + Lomb has an estimated long-term growth rate of 40.1% compared with the industry’s 15.2% growth. Shares of the company have rallied 43.3% compared with the industry’s 9.9% gain over the past year. BLCO’s earnings outpaced estimates in two of the trailing four quarters, matched once and missed on another occasion, the average surprise being 21.67%.
BLCO sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Insulet, sporting a Zacks Rank #1, has an estimated long-term growth rate of 19.4%, compared with the industry’s 9.3% growth. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 17.43%. PODD shares have dipped 59.6% compared with the industry’s 20.7% decline over the past year.
IDEXX Laboratories, carrying a Zacks Rank #2 (Buy), has an earnings yield of 2.2% against the industry’s negative 2.3% yield. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 5.5%. IDXX shares have risen 0.2% compared with the industry’s 2.4% growth over the past year.